Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Amgen Vs. J&J Score: 0 1


In Business This Week

AMGEN VS. J&J SCORE: 0-1

Amgen lost the first round in its dispute with Johnson & Johnson and must pay that company's Ortho Pharmaceuticals unit $164 million in damages. Amgen had licensed Ortho to sell its drug erythropoietin for uses other than kidney failure, but an arbitrator ruled that it had failed to help Ortho secure needed FDA approvals. Amgen, though, has outstanding claims against Ortho. Amgen charges that Ortho violated an agreement to help it develop two other drugs.EDITED BY HARRIS COLLINGWOOD


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus